Latest research on Erbitux

Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Erbitux indications

In the search for more tolerable and efficacious regimens, cetuximab (Erbitux, ImClone Systems, New Jersey, USA), an IgG1 monoclonal antibody against the ligand-binding domain of EGFR that enhances the cytotoxic effects of radiation in squamous cell carcinoma, was developed. [source, 2015]
PHA-665752 and cabozantinib demonstrated potent growth inhibition in METex14+ GC and CRC PDCs whereas lapatinib, an EGFR and HER2 inhibitor, and cetuximab (Erbitux), an EGFR targeting monoclonal antibody exhibited no such effects (Supplementary Figure S3C). [source, 2015]
Erbitux (ERB, cetuximab), a monoclonal therapeutic antibody, binds to the extracellular domain of epidermal growth factor receptor (EGFR) to prevent the activation and subsequent dimerization of the receptor, to decrease receptor activation and dimerization and result in inhibition of signal transduction and anti-proliferative effects. [source, 2015]
The accumulation of antibody in tumor local might induce stronger ADCC effect, and resulted in higher anti-tumor efficacy than Erbitux in a Hu-WBC NOD SCID xenograft mice model. [source, 2015]
An interesting study on the comparative hyperthermia effects of antibody (Erbitux, [ERB]) conjugated silica-gold nanoshells (SGNS) on epithelial tumor cells was conducted by Lee et al. ERB-coated SGNS showed excellent therapeutic efficacy under near infra-red irradiation. [source, 2015]
Cetuximab (Erbitux) is a monoclonal antibody that acts as competitor of natural ligands of the Epidermal Growth Factor Receptor (EGFR): Epidermal Growth Factor, Amphiregulin, Epiregulin, Transforming Growth Factor α. [source, 2014]
The effect was also antibody specific since the same construct with mouse IgG (a non-specific antibody) instead of Erbitux showed virtually no cell uptake (Figure 6B). [source, 2014]
Age did not affect the mutation frequency in the three types of cancer investigated, suggesting that K-ras mutation does not play a role in patient age Previously, an anticorrelation pattern of K-ras mutation status with the therapeutic effect, progression-free survival and overall survival following patient treatment with Erbitux was demonstrated (4,6). [source, 2014]
One common side effect of cetuximab (Erbitux) treatment is allergic reactions. [source, 2014]
In the present study, a dual-field chip that allows the control of concurrent stimulations by EGF and dcEF, was developed and used for investigating the effect of Erbitux on the electrotaxis of CL 1-5 cells. [source, 2013]